Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Sierra Oncology, Inc. | d522898dex322.htm |
| 10-K - FORM 10-K - Sierra Oncology, Inc. | d522898d10k.htm |
| EX-32.1 - EX-32.1 - Sierra Oncology, Inc. | d522898dex321.htm |
| EX-31.2 - EX-31.2 - Sierra Oncology, Inc. | d522898dex312.htm |
| EX-31.1 - EX-31.1 - Sierra Oncology, Inc. | d522898dex311.htm |
| EX-21.1 - EX-21.1 - Sierra Oncology, Inc. | d522898dex211.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-205693, 333-209897 and 333-216392 on Form S-8, and Registration Statement No. 333-212793 on Form S-3 of our report dated February 27, 2018, relating to the consolidated financial statements of Sierra Oncology, Inc. (formerly known as ProNAi Therapeutics, Inc.) and subsidiaries (the “Company”) appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2017.
/s/ Deloitte & Touche LLP
Grand Rapids, Michigan
February 27, 2018